Skip to Content
Merck
CN

Key Documents

View All Documentation

Y0001295

Spironolactone for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Spironolactone, 4-Pregnen-21-oic acid-17α-ol-3-one-7α-thiol γ-lactone 7-acetate, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C24H32O4S
CAS Number:
52-01-7
Molecular Weight:
416.57
NACRES:
NA.24
PubChem Substance ID:
329831347
UNSPSC Code:
41116107
MDL number:
MFCD00082250
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

spironolactone

manufacturer/tradename

EDQM

mp

207-208 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

InChI key

LXMSZDCAJNLERA-ZHYRCANASA-N

Gene Information

human ... NR3C2(4306)

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Spironolactone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Repr. 1B - STOT RE 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

监管及禁止进口产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Natalie A Christy et al.
The Annals of pharmacotherapy, 39(9), 1517-1521 (2005-08-04)
To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone. Studies and reports were located in MEDLINE (1966-January 2005), EMBASE, and International Pharmaceutical Abstracts through the second week of January 2005. Hirsutism
Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
Andrew S Bomback et al.
Nature clinical practice. Nephrology, 5(2), 74-75 (2008-11-26)
GianLuca Colussi et al.
Journal of hypertension, 31(1), 3-15 (2012-09-27)
Mineralocorticoid receptor antagonists (MRAs) are commonly used to reduce blood pressure, left-ventricular hypertrophy, and urinary albumin excretion in patients with essential hypertension or primary aldosteronism. Effects of MRAs on hypertensive organ damage seem to occur beyond what is expected from
View All Related Papers

Global Trade Item Number

SKUGTIN
Y000129504061833797525